Intrinsic Value of S&P & Nasdaq Contact Us

CSL Limited CSLLY OTC

Other OTC • Healthcare • Biotechnology • AU • USD

SharesGrow Score
77/100
6/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$307.00
+1104.4%

CSL Limited (CSLLY) generated $1.3B in operating cash flow for quarter ending 2025-12-31. After capital expenditures of $296.51M, free cash flow was $1.01B.

Free cash flow margin was 12.1% of revenue. Cash conversion ratio was 3.25x, indicating earnings are backed by cash.

The company returned $787.36M in dividends and $386.67M in share buybacks to shareholders during the quarter.

Criteria supported by this page:

  • HEALTH (67/100, Partial) — cash generation is adequate but may not fully cover debt in stressed conditions
  • MOAT (75/100, Pass) — $1.01B (12.1% margin) supports a durable competitive advantage
  • INCOME (70/100) — Cash conversion ratio was 3.25x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 77/100 with 6/7 criteria passed.

SharesGrow 7-Criteria Score
77/100
SG Score
View full scorecard →
VALUE
62/100
Price-to-Earnings & upside
→ Valuation
FUTURE
100/100
Analyst consensus
→ Forecast
PAST
100/100
→ Income
~
HEALTH
67/100
Debt-to-Equity & liquidity
Proven by this page
MOAT
75/100
Proven by this page
GROWTH
63/100
→ Income
INCOME
70/100
→ Income
CSL Limited Cash Flow History
Metric TTM Q2 FY2026 Q4 FY2025 Q2 FY2025 Q4 FY2024
Operating Cash Flow $6.71B$1.3B$2.44B$1.26B$1.71B
Capital Expenditure $-1.67B$-296.51M$-283.23M$-533M$-557.08M
Free Cash Flow $5.04B$1.01B$2.16B$726M$1.15B
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message